Document:

Exhibit 10.6

 

LABORATORY SERVICES AGREEMENT

 

PRIMESTUDY

 

This Laboratory Services Agreement (“Agreement”)
is made and entered into effective as of November 10, 2020 (“Effective Date”) by and between Anthem Health Insurance
and Amerigroup Corporation, whose principal place of business is 4425 Corporation Lane Virginia Beach, VA 23462 (hereinafter referred
to collectively as “Anthem”), and Sera Prognostics, Inc., whose principal place of business is 2749 East
Parleys Way, Suite 200, Salt Lake City, UT 84109 (“Laboratory”).

 

Background and Recitals

 

Anthem is a sponsor and administrator
of health insurance plans that provide benefits for, among other things, laboratory analyses of samples collected from insured individuals
among the services that are covered under its plans;

 

Laboratory has developed the
PreTRM® proteomic screening test to identify increased risks of adverse outcomes among pregnant women;

 

Laboratory has designed and
is sponsoring the Prematurity Risk Assessment combined with clinical Interventions for improving neonatal outcoMEs study to evaluate the
PreTRM® test (the “PRIME” study);

 

Anthem and Laboratory have
agreed to collaborate on the conduct of the PRIME study, and Laboratory has entered into a Work Order with HealthCore, Inc. for the
purpose of managing the conduct of the PRIME study;

 

Anthem has agreed to compensate
Laboratory for the PreTRM® tests performed pursuant to the PRIME study;

 

NOW, subject to the terms
and conditions of this Agreement, the parties desire that Anthem engage Laboratory to provide certain clinical laboratory services and
related services to support Anthem’s health insurance plans.

 

NOW, THEREFORE, for and in
consideration of the mutual promises and covenants set forth herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties agree as follows:

 

1.            Laboratory
Responsibilities

 

1.1            Services.
Subject to the terms and conditions of this Agreement, Laboratory shall provide the clinical laboratory services listed on Exhibit A,
attached hereto and incorporated herein by this reference, (the “Services”) as specifically requested by the treating
physicians or other qualified health care professionals from time-to-time for subjects enrolled in the PRIME study. All Services shall
be provided in accordance with all applicable federal, state and local laws, rules, and regulations, ordinances and licensure requirements,
and all requirements of third-party reimbursement sources (public or private), or other reimbursement sources covering laboratory services.
Laboratory shall use personnel properly licensed and qualified to perform laboratory services and shall maintain evidence of such compliance.

 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF
PUBLICLY DISCLOSED.

 

     

     

    

 

1.2           Pricing.
The fee for each PreTRM® test performed by Laboratory in accordance with the PRIME study is set out in the fee schedule attached
as Exhibit A, which is fully incorporated by reference into this Agreement.

 

1.3           Results.
Laboratory shall provide all results of Services (“Results”) in the form of
a written report delivered to the physician or other qualified health care professional ordering each test in accordance with the PRIME
study.

 

1.4           Processing.
Laboratory shall maintain a record of the daily intake of specimens and a system for identification of each specimen.

 

1.5           Support.
Laboratory shall make personnel available by telephone or electronic mail during normal business
hours to review Results, arrange for special tests as mutually agreed by the parties, and promptly communicate any new laboratory test
requisition processes to the ordering physician or other qualified health care professional.

 

1.6           Written
Policies. Laboratory has established written policies and procedures for detecting and preventing
fraud, waste, and abuse, and has also implemented a comprehensive compliance program and code of conduct, which complies with the standards
set forth in the OIG Compliance Program Guidance for Clinical Laboratories. Laboratory shall conduct its activities under this Agreement,
including all test orders, Services, supplies or materials provided under this Agreement, in accordance with the requirements of the applicable
federal and state laws, including those governing transportation of hazardous materials and record retention requirements.

 

1.7           Standards,
Qualifications, and Licensure. Laboratory represents and warrants that it is, and throughout the term of this Agreement shall remain,
CLIA certified. Laboratory shall provide immediate written notice of any change to its licensure, certification or accreditation status.
Laboratory represents and warrants that any pathologist providing Services under this Agreement is qualified, credentialed, and licensed
to practice medicine as shall be required to perform Services hereunder. Laboratory represents and warrants that it and its employees
and agents who perform the Services, possess the necessary skill, education, and training, and maintain all necessary federal and state
licenses and/or certifications required to perform such Services hereunder. The Services performed hereunder shall be performed at testing
facilities that remain duly licensed clinical laboratories under applicable federal, state and local law, and are accredited by an accrediting
organization. Laboratory will provide documentation of all credentials, licenses, qualifications and accreditation required in this Agreement
to Anthem upon request.

 

1.8           Waste.
Laboratory will be solely responsible for the disposal of any medical or other waste generated in the performance of the Services. Laboratory
shall comply with all laws and regulations applicable to such disposal.

 

1.9           Credentialing.
Laboratory represents that it meets all applicable Anthem credentialing standards.

 

    	 	2	 

     

    

 

2.             Billing
and Compensation by Anthem

 

2.1           List
Bill Submission and Payment. Except as otherwise provided herein, Laboratory will submit monthly invoices to Anthem for Services at the
rate per test conducted in the intervention arm of the PRIME Study (not the control arm), up to a [***] tests, as set forth in Exhibit A
(or other mutually acceptable and documented rate) within 15 days following the month in which such services were performed. Laboratory
agrees to accept the payments at the agreed upon rate as payment in full. Each invoice shall be in the form reasonably requested by Anthem,
and include all information necessary for Anthem to process payments to Laboratory . Anthem agrees to pay Laboratory undisputed amounts
within forty-five (45) days of the receipt of any invoice; provided, however, that Anthem shall have no obligation to pay for any Services
that are not timely invoiced.

 

2.2           Hold
Harmless. Laboratory shall not, under any circumstance, including: (i) nonpayment of moneys
due Laboratory by Anthem, (ii) insolvency of Anthem, or (iii) breach of this Agreement, bill, charge, collect a deposit, seek
compensation, remuneration, or reimbursement from, or have any recourse against an enrolled subject, dependent of an enrolled subject,
or any persons acting on their behalf, for Services.

 

2.3            Basis
of Pricing. The parties acknowledge and agree that the pricing set out in this Agreement is limited
to the tests performed under the PRIME study protocol, and may not be used to set any future reimbursement amounts for the PreTRM®
test. The parties further acknowledge and agree that the aggregate services hereunder do not exceed those that are reasonable and necessary
for a legitimate business purpose, and that the compensation to be provided hereunder has not been determined in a manner that takes into
account the volume or value of any referrals or other business generated between the parties.

 

3.            Term &
Termination

 

3.1           Term.
This Agreement shall commence on the Effective Date and remain in effect until the conclusion of the PRIME study, unless otherwise terminated
as provided herein. Thereafter, this Agreement may be renewed for additional terms of one (1) year each upon mutual agreement of
the parties.

 

3.2           Termination.
Notwithstanding anything herein to the contrary, this Agreement may be terminated as follows: (i) by cause by either party upon the
default by the other party of any term, covenant or condition of this Agreement, where such default continues for a period of ten (10) days
after the defaulting party receives written notice thereof from the other party such default; (ii) without cause by either party
effective at any time after at least thirty (30) days prior written notice to the other party in which case the Agreement shall terminate
on the future date specified in such notice, except that no such termination without cause shall take effect prior to the first annual
anniversary of the Effective Date; (iii) by either party upon notice to the other party following the filing of voluntary or involuntary
bankruptcy by either party; or (iv) by either party immediately upon notice to the other party in the event of either party’s
loss of license, accreditation, or certification necessary for its performance hereunder.

 

4.             Record
Retention. Laboratory agrees to keep and maintain any and all records, including but not limited to medical and financial records,
for services rendered by Laboratory to Anthem as may be required by federal, state, or local government laws and Anthem policies. Laboratory
shall provide a copy of such records to Anthem upon request.

 

    	 	3	 

     

    

 

5.             Confidential
Information.

 

a)             Confidential
Information is any information provided pursuant to or in furtherance of this Agreement by a Disclosing Party to a Receiving Party that
is clearly marked as “confidential” or that a reasonable person in like circumstances would understand to be confidential
or proprietary. “Confidential Information” does not include Protected Health Information, as that term is defined at 45 C.F.R.
 § 160.103 and shall not apply to information that:

 

		(i)	was known to Receiving Party at the time of disclosure hereunder, as evidenced by Receiving Party’s
contemporaneous written or electronic records;

 

		(ii)	becomes generally known to the public through no fault of Receiving Party or anyone doing work under its
direction pursuant to the terms of this Agreement;

 

		(iii)	is disclosed to Receiving Party by a third person who has a right to make such disclosure without an obligation
of confidentiality to Disclosing Party; or

 

		(iv)	is developed independently by Receiving Party without use of the Disclosing party’s Confidential
Information, as evidenced by Receiving Party’s contemporaneous written or electronic records.

 

b)             Receiving
Party shall not use Confidential Information, except in furtherance of this Agreement, or disclose Confidential Information to third parties
in a manner that is inconsistent with the terms of this Section. Except as stated herein, a Receiving Party shall restrict access to Disclosing
Party’s Confidential Information to Receiving Party’s employees and contractors with a need to know for the purpose of administering
or implementing this Agreement or for the purpose of providing legal, actuarial, or accounting services to Receiving Party, and only to
the extent such employees and contractors agree to be bound by confidentiality and use restrictions at least as restrictive as those set
forth herein. Receiving Party shall be responsible for any unauthorized use or disclosure of the Disclosing Party’s Confidential
Information by any person or entity to which the Receiving Party discloses such Confidential Information.

 

c)             Upon
termination of this Agreement, Receiving Party shall return to Disclosing Party all documents or other materials that contain Disclosing
Party’s Confidential Information or destroy all copies thereof.

 

d)             If
the Receiving Party is required under a final judicial or governmental order to disclose any Confidential Information received from the
Disclosing Party, the Receiving Party may disclose the Confidential Information, provided that the Receiving Party gives the Disclosing
Party sufficient prior notice to contest such order and the Receiving Party discloses only such portions of the Confidential Information
as is required by such order.

 

    	 	4	 

     

    

 

6.              HIPAA
Requirements. Without limiting the foregoing, the parties acknowledge that each party is a “covered entity” as that term
is defined at 45 C.F.R. § 160.103. As such, the parties agree to comply with applicable requirements of the Health Insurance Portability
and Accountability Act of 1996, as codified at 42 U.S.C. § 1320d et seq. (“HIPAA”), the Health Information Technology
for Economic and Clinical Health Act, as each may be amended from time to time, and any current and future regulations promulgated thereunder,
including without limitation the federal privacy regulations contained at 45 C.F.R. Part 160 and Part 164, Subpts. A and E (the
 “Federal Privacy Regulations”), the federal security standards contained at 45 C.F.R. Part 160 and Part 164, Subpts.
A and C, the federal breach notification rules contained at 45 C.F.R. Part 160 and Part 164, Subpts. A and D, and the federal
standards for electronic transactions contained at 45 C.F.R. Parts 160 and 162, all collectively referred to herein as “HIPAA Requirements.”
The parties agree not to use or further disclose any Protected Health Information, as defined in the Federal Privacy Regulations, other
than as permitted by HIPAA Requirements.

 

7.              Insurance
Coverage. During the term of this Agreement, Laboratory shall maintain general and professional liability insurance including coverage
for product liability and clinical trials liability in the amount of $[***] per occurrence and $[***] annual aggregate or
such higher coverage as may be required by law. Proof of said insurance coverage shall be supplied to Anthem upon request.

 

8.              Indemnification.
Laboratory shall indemnify, defend, and hold Anthem, its directors, officers, agents, and employees, harmless from and against any judgments,
damages, losses, costs, and expenses (including, without limitation, reasonable attorneys’ fees) arising from, or related to, any
allegation, demand, claim, action or proceeding to the extent arising out of the Services, or Laboratory’s breach of this Agreement
or applicable law, or Laboratory’s negligent acts or omissions.

 

Anthem shall indemnify, defend,
and hold Laboratory, its directors, officers, agents, and employees, harmless from and against any judgments, damages, losses, costs,
and expenses (including, without limitation, reasonable attorneys’ fees) arising from, or related to, any allegation, demand, claim,
action or proceeding to the extent arising out of the Services, or Anthem’s breach of this Agreement or applicable law, or Anthem’s
negligent acts or omissions, except to the extent that such judgments, damages, losses, costs and expenses were caused by Laboratory’s
negligence, willful misconduct or failure to comply with its obligations under this Agreement.

 

9.              Fraud
and Abuse. The parties expressly acknowledge that the compensation payable hereunder is fair market value for the items purchased
and/or the services rendered, and that nothing contained herein shall require referrals for items or services between the parties. Neither
party will knowingly or intentionally conduct itself in such a manner as to violate any federal or state law, rule or regulation
applicable to the items purchased or the services rendered hereunder, including but not limited to any fraud and abuse provisions relating
to the Medicare and Medicaid Programs. The parties also agree that the benefits to either party hereunder do not require, are not payment
for, and are not in any way contingent upon the admission, referral, or other arrangement for the provision of any item or service reimbursed
under any federal or state health care program, including, without limitation, Medicare or Medicaid.

 

    	 	5	 

     

    

 

10.           Miscellaneous

 

10.1        Assignment.
Laboratory may not assign this Agreement, or any rights or obligations hereunder, without Anthem’s prior written consent, which
consent shall not be unreasonably withheld, delayed, or conditioned. Subject to the foregoing, this Agreement shall inure to the benefit
and be binding upon Anthem and its successors and assigns and Laboratory and its successors and assigns.

 

10.2        Changes
in Law. This Agreement shall be construed to be in accordance with applicable federal and state
laws. In the event there is a change in such laws, whether by statute, regulation, agency, or judicial decision that has any material
effect on any term of this Agreement, then the applicable term(s) of the Agreement shall be subject to renegotiation and any affected
party may request renegotiation of the affected term or terms of this Agreement, upon written notice to the other party, to remedy such
condition.

 

The parties expressly recognize
that upon request for renegotiation, each party has a duty and obligation to the other only to renegotiate the affected term(s) in
good faith and, further, each party expressly agrees that its consent to proposals submitted by the other party during renegotiation efforts
shall not be unreasonably withheld.

 

Should the parties be unable
to renegotiate the term or terms so affected so as to bring it/them into compliance with the statute, regulation, or judicial opinion
that rendered it/them unlawful or unenforceable within ten (10) days of the date on which notice of a desired renegotiation is given,
then either party shall be entitled, after the expiration of said ten (10) day period, to terminate this Agreement upon ten (10) additional
days written notice to the other party.

 

10.3        Compliance
with Laws. Laboratory warrants that it is and shall remain in compliance with all applicable
federal, state, and local laws, regulations, and standards relating, including but not limited to all laws and regulations related to
health, safety, and environmental standards, and (ii) all such laws related to the provision of Services purchased pursuant to this
Agreement.

 

10.4        Enforceability.
In the event any provision of this Agreement is found to be unenforceable or invalid, such provision shall be severable from this Agreement
and shall not

 

affect the enforceability or validity of any other provision contained
in this Agreement.

 

10.5        Entire
Agreement. This Agreement may be executed in one or more counterparts, all of which together
shall constitute only one Agreement. This Agreement contains the entire understanding between the parties and supersedes and terminates
any prior agreement(s) between the parties hereto. No amendments or additions to this Agreement shall be binding unless such amendments
or additions are in writing and signed by the parties, except as herein otherwise provided.

 

10.6        Force
Majeure. Neither party shall be liable for a delay in its performance of its obligations and
responsibilities under this Agreement due to extraordinary causes beyond its control, including, but not limited to, war, act of terrorism,
pandemics, embargo, national emergency, insurrection or riot, acts of the public enemy, fire, flood, or other natural disaster (“Force
Majeure Event”); provided that said party has taken reasonable measures to notify the other, in writing, of the delay. Further,
in the event either party is unable to meet its obligations hereunder because of such force majeure, and such inability continues for
a period of thirty (30) days or more, then either party may terminate this Agreement effective immediately without further obligation
to the other except as to delivery of and payment for the Services consistent with the terms of this Agreement.

 

    	 	6	 

     

    

 

10.7        Governing
Law. This Agreement and the rights and obligations of the parties hereto shall be governed by
and construed and enforced in accordance with the substantive laws of the State of Utah, without regard to its principles of conflicts
of laws.

 

10.8        Independent
Contractors. Each party shall be considered to be an independent party and shall not be construed
to be an agent or representative of the other party, and therefore, has no liability for the acts or omissions of the other party. In
addition, neither party, nor any of its employees, agents, or subcontractors, shall be deemed to be employees or agents of the other party.
Therefore, neither party nor any of its employees, agents, or subcontractors, shall be entitled to compensation, workers compensation,
or employee benefits of the other party by virtue of this Agreement.

 

10.9        Non-Solicitation.
No party may, directly or indirectly, solicit, recruit, or otherwise encourage any employee of
the other party to leave his or her employment with that other party for any reason. This restriction applies during the term and for
a period of twelve (12) months after the termination or expiration of this Agreement. The preceding sentence does not, however, prohibit
either party from: (i) soliciting employment by placement of general advertisements for employees on any internet site, in newspapers,
or via other media of general circulation not specifically directed at the employees of the other party; (ii) soliciting persons
identified through employment search firms that are not specifically directed at the employees of the other party; or (iii) soliciting
or hiring any person who contacts the hiring party on his or her own initiative without any prior solicitation or recruitment (other than
advertisements of the type contemplated by the preceding clauses).

 

10.10      Remedies.
In addition to those remedies provided herein, each party shall have available all remedies provided by law.

 

10.11      Section and
Other Headings. The article and other headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

 

10.12      Waiver.
The waiver of a breach of this Agreement or the failure of a party to exercise any right under this Agreement shall in no event constitute
a waiver as to any other breach, whether similar or dissimilar in nature, or prevent the exercise of any right under this Agreement.

 

10.13       Audit.
Anthem may, upon reasonable notice, audit any and all work or expense records of Laboratory relating to the Services provided hereunder.
Laboratory shall have the right to exclude from such inspection any of its confidential or proprietary information that is unrelated to
this Agreement, which was not otherwise provided to Anthem as a part of this Agreement. Laboratory further agrees to maintain its books
and records relating to System provided hereunder for a period of two (2) years from the date such work was completed, and to make
such books and records available to Anthem, during normal business hours, at any time or times within the two-year period. Any such audit
will be at Anthem’s expense.

 

    	 	7	 

     

    

 

10.14      Notice.
This Agreement, including any attachments, may be amended or modified only by an instrument of equal formality signed by duly authorized
representatives of the respective parties. All notices, requests, demands, or other communications hereunder other than day-to-day communications
within the duties of the representatives shall be in writing and shall be deemed given if personally delivered or mailed to the address
set forth below:

 

		Laboratory:	Sera Prognostics, Inc.

2749 East Parleys Way

Suite 200

Salt Lake City, UT 84109

 

		Anthem:	Anthem Inc.

4425 Corporation Lane

Virginia Beach, VA 23462

 

Any changes in the above addresses
for notice shall be provided to the other party to this Agreement within five (5) days of such change.

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement on the day and year first above written.

 

	Anthem Inc.	 	Sera Prognostics, Inc.
	 	 	 
	By:	/s/ Michael Hodgins	 	By:	/s/ Gregory Critchfield
	 	 	 
	Title:	Director, Strategic Sourcing	 	Title:	President and CEO
	 	 	 
	Date:	1/8/2021	 	Date:	11/11/2020

 

    	 	8	 

     

    

 

Exhibit A

 

Laboratory Services Fee Schedule

 

[***]

 

    	 	9Exhibit 10.7.1

 

Confidential

 

COMMERCIALIZATION AGREEMENT

 

This Commercialization Agreement
(“Agreement”) is effective as of January 9, 2017 (“Effective Date”) and is entered into by and between
Sera Prognostics, Inc. (“Sera”), a Delaware corporation with its principal place of business at 2749 East Parleys Way,
Suite 200, Salt Lake City, Utah 84109, and Laboratory Corporation of America Holdings (“LabCorp”), a Delaware corporation
with its principal place of business at 531 South Spring Street, Burlington, North Carolina 27215. Each of Sera and LabCorp is referred
to herein as a “Party” and together as the “Parties.”

 

BACKGROUND

 

		A.	Sera is a diagnostics company that develops, commercializes, and performs a prognostic test in its CLIA-certified
laboratory referred to as the PreTRM® test, which is a clinical blood test for early individualized risk assessment of spontaneous
premature birth (the “Test”).

 

		B.	LabCorp provides leading-edge medical laboratory tests and services through a national network of primary
clinical laboratories and specialty testing laboratories.

 

		C.	[***].

 

NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the
receipt and sufficiency of which are acknowledged, the Parties agree as follows.

 

		1.	DEFINITIONS

 

Capitalized terms used herein
shall have the definitions set forth in this Article 1 or elsewhere herein.

 

1.1           
“Affiliate” means, with respect to a Party to this Agreement, any current or future Entity which controls, is
controlled by, or is under common control with such Party, but only for so long as such control exists. For purposes of this definition
only, “control” means direct or indirect ownership of at least fifty percent (50%) of the shares or other equity interests
of the subject Entity entitled to vote in the election of directors (or, in the case of an Entity that is not a corporation, for the election
of the corresponding managing authority).

 

1.2          
“Commercialize” means to advertise, market, promote, offer for sale, sell and distribute, and to accept orders,
collect fees and book revenue for sales of Tests (and “Commercialization” shall have the correlative meaning).

 

1.3           
“Commercially Reasonable Efforts” means the carrying out of activities using good faith commercially reasonable
and diligent efforts to achieve a goal, and using the efforts that a similarly situated company would reasonably devote to a product
of similar market potential or profit potential at a similar stage in development or product life resulting from its own research efforts,
based on conditions then prevailing and taking into account, without limitation, issues of safety and efficacy, product profile, the
competitiveness of alternative products in the marketplace, the likely timing of the product’s entry into the market, the patent
and other proprietary position, and the status of the approval process, the commercial potential and profitability, and other relevant
scientific, medical, technical and commercial factors.

 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL
IF PUBLICLY DISCLOSED. 

 

     

     

    

 

1.4           
“Control” or “Controlled” means the possession by Sera of the ability to grant a license
or sublicense of intellectual property rights as provided for herein without violating the terms of any arrangement or agreements between
it and any third party.

 

1.5           
“Entity” means a person, corporation, partnership, association, limited liability company, unincorporated organization,
firm, or other entity.

 

1.6           
“Field” means the prediction of a patient’s likelihood to deliver a baby at less than thirty seven (37)
weeks of gestation. For clarity, pharmaceutical collaborations and clinical trials are outside the Field.

 

1.7           
[***].

 

1.8          
“Legal Requirements” means any applicable national, federal, state or local law, rule, ordinance or regulation,
or formal administrative agency final guidance or published final interpretation, in the Territory.

 

1.9           
“Provider” means a healthcare provider authorized and licensed to provide obstetrics services to patients within
the Territory.

 

1.10         
[***].

 

1.11         
“Sample” means any fluid sample extracted from a Provider’s patient as necessary to perform the Test.

 

1.12         
“Territory” means the United States.

 

1.13         
[***].

 

		2.	DISTRIBUTION RIGHTS AND OBLIGATIONS

 

2.1           
[***].

 

2.2           
[***].

 

2.3           
[***].

 

2.4           
[***].

 

2.5           
[***].

 

2.6           
[***].

 

    2

     

    

 

2.7          
 Independent Contractor. Each Party shall perform its services under this Agreement as an independent contractor and not
as an employee or agent of the other Party or any of its parents, subsidiaries, or affiliates. Neither Party is authorized to assume or
create any obligation or responsibility, express or implied, on behalf of, or in the name of, the other Party or to bind the other Party
in any manner, except that Sera will perform all Tests that are ordered in compliance with the process described in Section 3. Without
limiting the generality of the foregoing, neither Party (a) shall have the right to enter into any contracts or commitments in the name
of, or on behalf of, the other Party, and (b) shall obligate or purport to obligate the other Party by issuing or making any warranties
or guaranties with respect to Tests to any third party that are not provided or approved in writing in advance by the other Party. Neither
Party shall be entitled to any benefits, coverages or privileges, including, without limitation, social security, unemployment, medical
or pension payments, made available to employees of the other Party.

 

2.8           
[***].

 

2.9           
[***].

 

2.10         
[***].

 

2.11         
[***].

 

2.12         
[***].

 

2.13         
[***].

 

2.14         
[***].

 

2.15         
[***].

 

2.16         
[***].

 

		3.	SAMPLE PROCESSING AND TESTING

 

3.1          
SOPs. Sera and LabCorp shall use diligent and good faith efforts to agree upon standard operating procedures for LabCorp’s
acceptance of orders for Tests, collection, processing and shipment of Samples to Sera, and Sera’s provision of Sera Results Reports
(defined below) (“Intercompany SOPs”) for each Test within thirty (30) days of the Effective Date. Sera acknowledges
that LabCorp is not responsible for ensuring that the collection, preservation, shipping and handling specifications established in the
Intercompany SOPs are sufficient to ensure the viability of Samples for performance of the Test. Each Intercompany SOP may only be amended
by the Parties in writing. Neither Party shall change nor deviate from an Intercompany SOP without the other Party’s prior written
approval of the proposed change or deviation. Sera shall maintain written documentation of its own technical standard operating procedures
for its performance of the Tests (“Sera SOPs”), which shall constitute Sera’s Confidential Information. For clarity,
the Sera SOPs shall not form part of the Intercompany SOPs.

 

    3

     

    

 

3.2           
Sample Collection, Processing and Shipment by LabCorp. LabCorp agrees that it will be responsible for (a) collecting Samples
at LabCorp facilities from customers who have ordered the Test; (b) procuring the supplies needed for each patient draw; (c) labeling
and processing such Samples (whether ordered in connection with other testing to be performed by LabCorp or as a standalone test); (d)
packaging the Samples; and (e) shipping the Samples to Sera’s CLIA-certified, licensed laboratories located at 2749 Parleys Way,
Suite 200, Salt Lake City, UT 84109 (the “Licensed Facilities”) for performance of the Tests, all in accordance with
the Intercompany SOPs. Sera acknowledges that LabCorp may route samples through its regional laboratories, so long as such routing complies
with the Sera SOPs. LabCorp shall not deliver any Samples to Sera that LabCorp knows is insufficient for purposes of performing a Test.

 

3.3           
[***].

 

3.4           
[***].

 

3.5           
Performance of Tests. Sera will perform Tests on Samples received from LabCorp at the Licensed Facilities in accordance
with (i) the analytical, clinical and performance standards set forth on Exhibit E attached hereto and (ii) the Intercompany SOPs.
[***].

 

3.6           
[***].

 

3.7           
[***].

 

3.8           
[***].

 

3.9           
Licensed Facilities. Sera shall perform the Services only at its Licensed Facilities and Sera may change the location of
the Licensed Facilities to substantially equivalent and appropriately certified, accredited, licensed laboratory facilities within the
USA upon sixty (60) days’ prior written notice to LabCorp. LabCorp’s designated representatives may visit the Licensed Facilities
upon reasonable advance notice and during Sera’s normal business hours to observe the performance of the Services and to verify
compliance with the Intercompany SOPs, subject to compliance with Sera’s onsite policies and processes.

 

3.10         
Governmental Permits and Approvals. Each Party will obtain and maintain all applicable professional licenses, permits, certifications,
authorizations, and approvals as may be required for the performance of its hereunder, and each Party will be solely responsible for any
fees associated with any licenses, permits, certifications, authorizations, or approvals. Sera will use commercially reasonable efforts
to obtain and receive New York Approval as soon as practicable, and will notify LabCorp promptly upon the occurrence of New York Approval.

 

3.11         
Retention of Records and Samples. Sera and LabCorp shall retain and preserve accurate and complete records and pertinent
Samples related to any Tests performed by Sera under this Agreement in conformity with company policies and consistent with applicable
Legal Requirements. Upon written request, each Party shall make available for review by the other all such records and preserved materials
as may be reasonably required or requested.

 

3.12         
[***].

 

    4

     

    

 

		4.	COMPENSATION

 

4.1           
[***].

 

4.2           
[***].

 

4.3           
[***].

 

4.4           
[***].

 

4.5           
[***].

 

4.6           
[***].

 

4.7           
[***].

 

		5.	CLINICAL STUDIES AND COMPLIANCE

 

5.1           
[***].

 

5.2           
Compliance with Laws. LabCorp and Sera each agree to perform their respective obligations under this Agreement in compliance
with all Legal Requirements and all applicable regulations, rules, and policies of third party payors that pay for the Tests. The terms
of this Agreement are intended to be in compliance with Legal Requirements applicable on the Effective Date, including, but not limited
to the federal health care anti-kickback statute (42 U.S.C. § 1320a-7b), and applicable state law equivalents, as well as applicable
state law prohibitions on professional fee splitting. Should legal counsel for either Party reasonably conclude that any portion of this
Agreement is or may be in violation of such Legal Requirements, or subsequent enactments by any governmental authorities, that Party shall
give written notice and the Parties will negotiate in good faith to amend this Agreement to comply with such Legal Requirements. In the
event that the Parties are unable to agree upon such an amendment, either Party may terminate this Agreement.

 

5.3           
Privacy. LabCorp and Sera each agree to protect the privacy and provide for the security of any information that relates
to a patient’s past, present, or future physical or mental health or condition in accordance with the Health Insurance Portability
and Accountability Act of 1996, Public Law 104-191, and all regulations promulgated thereunder at 45 C.F.R. parts 160 through 164, as
amended by the federal Health Information Technology for Economic and Clinical Health Act (“HITECH Act”) and its implementing
regulations, as may be modified or amended (collectively “HIPAA”), and any other applicable federal and state laws
and regulations. The Parties acknowledge and agree that they are both “covered entities” providing “treatment”
for patients as those terms are defined under HIPAA. Both parties acknowledge that they have developed and implemented policies, procedures,
and training programs reasonably designed to protect the privacy and security of patient information in accordance with HIPAA’s
privacy, security, and breach notification regulations. Sera shall not use any information received from LabCorp to contact a patient
directly without LabCorp’s prior written consent.

 

    5

     

    

 

5.4          
 Participation in Federal Health Care Programs. LabCorp and Sera respectively represent, warrant and covenant to the other
that:

 

5.4.1       
It, and its owners, directors, officers, agents, or employees are, as of the Effective Date, and for the remainder of the term
of this Agreement, will be, eligible to participate in the federal health care programs as defined in Section 1128B of the Social Security
Act (42 U.S.C. 1320a-7b(f)) or any state health care program as defined in Section 1128B of the Social Security Act (42 U.S.C. 1320a-7b(h)).

 

5.4.2       
Neither it, nor any of its owners, directors, officers, agents, or employees has been, as of the Effective Date, nor during the
term of this Agreement, will be, sanctioned by the DHHS Office of the Inspector General as set forth in the List of Excluded Individuals/Entities
Database or excluded by the General Services Administration as set forth in Excluded Parties List System.

 

5.4.3       
It shall notify the other Party promptly in the event of any adverse action relating to its license, permit, certification or right
to receive reimbursement from any federally funded health care program.

 

5.5          
Non-Discrimination. Each Party will perform its obligations hereunder in compliance with all federal and state laws prohibiting
discrimination on the basis of race, color, religion, sex, national origin, handicap, or veteran status.

 

		6.	INVESTMENT

 

[***].

 

		7.	INDEMNIFICATION; LIMITATION OF LIABILITY AND INSURANCE.

 

7.1           
Indemnification.

 

7.1.1       
LabCorp will defend, indemnify and hold harmless Sera and its Affiliates, and their respective shareholders, members, partners,
directors, officers, employees, and agents (“Sera Indemnified Parties”) from and against any and all third party claims,
actions, and proceedings alleging damages, liabilities, losses, costs and/or expenses and brought against any of the Sera Indemnified
Parties to the extent arising from (a) LabCorp’s violation of a Legal Requirement in connection with its performance of this Agreement;
(b) any negligent act or omission or intentional misconduct or omission of LabCorp in relation to its obligations under this Agreement;
(c) the breach of Section 9 by LabCorp; (d) any representations or warranties made by LabCorp in respect of Tests that are inconsistent
with, or broader than, the then-current representations and warranties published, provided, or approved by Sera in writing; (e)
any deviation from the results included in the Sera Results Report as compared to the results actually reported by LabCorp to the customer
(including, without limitation, any errors in reproducing the results or any information relating to the results or use or interpretation
thereof which was not included in the Sera Results Report as provided to LabCorp); (f) any Test results which are incorrect as a result
of procedures or processes or other activities within LabCorp’s control; and (g) personal injury caused by LabCorp personnel in
their drawing, handling, storing and shipping of Samples and related patient information.

 

    6

     

    

 

7.1.2       
 Sera will defend, indemnify and hold harmless LabCorp and its Affiliates, and their respective shareholders, members, partners,
directors, officers, employees, and agents (“LabCorp Indemnified Parties”) from and against any and all third party
claims, actions, and proceedings alleging damages, liabilities, losses, costs and/or expenses and brought against any of the LabCorp Indemnified
Parties to the extent arising from (a) Sera’s violation of a Legal Requirement in connection with its performance of this Agreement;
(b) any negligent act or omission or intentional misconduct or omission of Sera in relation to its obligations under this Agreement; (c)
the breach of Section 9 by Sera; (d) any Test results (as provided by Sera to LabCorp hereunder) which (1) are incorrect as a result of
laboratory procedures or processes or other activities within Sera’s control, or (2) are performed by Sera outside the standards
as set forth in Exhibit E or otherwise not in conformance with the sensitivity or specificity standards set by Sera for the Test
as of the time the Test is performed; (e) any Test tests that were not performed by Sera in accordance with Sera SOPs in effect as of
the time the test was performed; (f) any incomplete Test results as provided by Sera to LabCorp hereunder; and (g) any actual or alleged
infringement (including direct or indirect, joint or divided infringement, as the case may be) or misappropriation of any patent or other
intellectual property rights based upon the performance of the Test or based upon the Sera Mark (unless used by LabCorp other than in
strict accordance with this Agreement).

 

7.1.3       
A Party’s obligations to indemnify the other Party pursuant to this Section 7.1 is conditioned upon the indemnified Party:
(i) providing the indemnifying Party with prompt written notice of such claim, action, or proceeding (although failure to provide notice
promptly shall not relieve the indemnifying Party of its obligations unless such failure materially prejudices the indemnifying Party’s
ability to defend such claim, action or proceeding); (ii) permitting the indemnifying Party to assume and solely control the defense of
such claim, action, or proceeding and all related settlement negotiations, with counsel chosen by the indemnifying Party; and (iii) cooperating
at the indemnifying Party’s request and expense with the defense or settlement of such claim, action, or proceeding which cooperation
must include providing reasonable assistance and information. No indemnified Party will enter into any settlement agreement for which
it will seek indemnification under this Agreement from the indemnifying Party without the prior written consent of the indemnifying Party.
Nothing herein restricts the right of a Party to participate in a claim, action, or proceeding through its own counsel and at its own
expense.

 

7.2          
Limitation of Liability. EXCEPT WITH RESPECT TO DAMAGES CAUSED BY FRAUD, INTENTIONAL MISCONDUCT, A BREACH OF SECTION 8 (CONFIDENTIALITY)
OR BY A PARTY’S VIOLATION OF APPLICABLE LEGAL REQUIREMENTS, AND EXCEPT FOR AMOUNTS OWED BY A PARTY PURSUANT TO ITS INDEMNIFICATION
OBLIGATIONS IN SECTION 7.1, NEITHER PARTY WILL BE LIABLE TO THE OTHER FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR SIMILAR
LOSSES OR DAMAGES SUFFERED BY SUCH PARTY, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

 

7.3           
Insurance. Each Party shall maintain in full force and effect from a third party that is rated “A” or “A-”
in Best’s Insurance Guide, or is otherwise reasonably acceptable to the other Party, at a minimum the following insurance coverage
for its operations in the Territory:

 

    7

     

    

 

(i)                
 Automobile liability covering all vehicles owned, non-owned, hired and leased in an amount not less than $[***] per claim (combined
single limit for bodily injury and property damage).

 

(ii)             
Commercial general liability insuring against bodily injury, property damage, contractors’ completed operations and contractual
liability with a combined single limit of not less than $[***] per claim and $[***] in the aggregate.

 

(iii)           
Umbrella/Excess Liability coverage of not less than $[***].

 

Insurance carried on a claims made basis shall
have a reporting tail of at least three years after the expiration or termination of this Agreement to cover all claims. This can be purchased
at termination of the Agreement. For the avoidance of doubt, any policy amounts or limitations shall not in any event be construed as
limitations on a Party’s liability under the Agreement. After receipt of written request, each Party shall furnish the other Party
with certificates of insurance evidencing the above coverages.

 

		8.	CONFIDENTIALITY

 

8.1          
Confidentiality. The Parties acknowledge that they may exchange confidential or proprietary information pursuant to this
Agreement (“Confidential Information”), whether written, verbal, or tangible. Confidential Information shall not include
information that the receiving Party can demonstrate (a) is or becomes a part of the public domain through no wrongful act or omission
of the receiving Party, (b) is or was in the receiving Party’s lawful possession prior to receipt from the disclosing Party, as
evidenced by the receiving Party’s records kept in the ordinary course of its business, (c) is disclosed to the receiving Party
by a third party entitled to disclose such Confidential Information, other than disclosure on behalf of the disclosing Party, or (d) was
independently developed by the receiving Party without use of or access or reference to the Confidential Information of the disclosing
Party, as evidenced by the receiving Party’s records kept in the ordinary course of its business. Each Party agrees that, during
the term of this Agreement and thereafter, it shall not, directly or indirectly, (i) use the other Party’s Confidential Information
for any reason other than to perform its obligations or exercise its rights under this Agreement, or (ii) disclose or otherwise make available
the other Party’s Confidential Information to any third parties, except in either case (A) as authorized by such other Party in
writing, (B) as expressly permitted herein, or (C) to the extent required by applicable Legal Requirements, in which case it shall promptly
notify the other Party in writing of the requirement so that the other Party may seek a protective order or confidentiality treatment,
and it shall cooperate with the other Party, at the other Party’s request and expense, in any such efforts. In no event shall Sera
use any Confidential Information of LabCorp to solicit any customers of LabCorp inside or outside the Territory during or after the term
of this Agreement.

 

8.2           
Terms of Agreement. Each of the Parties shall not disclose to any third party the terms of this Agreement without the prior
written consent of the other Party, except in confidence to its business or legal advisors, investors, and sources of financing, in each
case on a need-to-know basis under circumstances that reasonably ensure the confidentiality thereof, or to the extent required by law,
rule, regulation or governmental authority, including applicable rules of any securities exchange. If the terms of this Agreement are
required to be publicly disclosed by applicable Legal Requirements, the disclosing Party shall seek confidential treatment for the terms
and conditions of this Agreement to the fullest extent permitted by applicable laws, rules and regulations. Prior to seeking such confidential
treatment, the disclosing Party shall provide the other Party with a copy of the proposed disclosure showing the disclosing Party’s
proposed redactions of the document, and shall consult with the other Party and the other Party’s counsel and provide them with
a reasonable opportunity to request the inclusion of specified provisions or redactions in any request for confidential treatment.

 

    8

     

    

 

		9.	REPRESENTATIONS AND WARRANTIES

 

9.1           
By Sera. Sera represents, warrants and covenants to LabCorp that:

 

9.1.1       
This Agreement is a legal and valid obligation binding upon Sera and enforceable in accordance with its terms, subject to generally
applicable Legal Requirements, and the execution, delivery and performance of this Agreement by Sera does not conflict with any agreement,
instrument or understanding to which Sera is a party or by which it is bound.

 

9.1.2       
No consent of, or payment to, any third party is required for Sera to grant the rights and licenses to LabCorp as set forth herein,
or for Sera to enter into this Agreement.

 

9.1.3       
Sera’s employees who will be performing the Tests hereunder are qualified to do so, and possess the necessary skill, education,
training, and where required by any applicable Legal Requirements, Sera and its employees have the necessary federal and state licenses
or certificates, to perform such testing services. Copies of such licenses or certificates shall be provided to LabCorp upon written request,
in addition to such quality assessment information as reasonably requested by LabCorp.

 

9.1.4       
Sera shall comply with current good laboratory practice as required by the Clinical Laboratory Improvement Amendments of 1988 under
42 USC 263a (CLIA’88), FDA regulations for Protection of Human Subjects in Research as published in 21 CFR Parts 50, 56 and 812
and all applicable College of American Pathologists rules, regulations, orders and guidances, and the requirements with respect to current
good laboratory practices prescribed by other similar authorities in the Territory, and shall perform all its obligations under this Agreement
in a professional and workmanlike manner.

 

9.1.5       
Sera shall maintain an adequate and appropriate disaster recovery plan for performance of Tests hereunder.

 

9.1.6       
All information and other content Sera provides to LabCorp for use in the sales, marketing and promotion of the Test shall be accurate
and not deceptive or fraudulent.

 

9.1.7       
As of the Effective Date, neither Sera nor any of its officers, directors, employees or owners have been debarred, suspended, declared
ineligible or excluded from participation in any federal or state healthcare program and during the term of this Agreement no officer,
director or employee that has been debarred, suspended, declared ineligible or excluded from participation in any federal or state healthcare
program shall perform any services under this Agreement.

 

    9

     

    

 

9.1.8       
 To Sera’s knowledge, as of the Effective Date, there is no unauthorized use, infringement or misappropriation by any third
parties of the intellectual property Controlled by Sera and used in its performance of this Agreement.

 

9.1.9       
To Sera’s knowledge, as of the Effective Date, there is no pending or threatened litigation which alleges that Test infringes
upon any third party rights.

 

9.1.10   
To Sera’s knowledge, as of the Effective Date, there are no valid patent claims or other intellectual property rights of
a third party that would be infringed by Sera’s performance of the Test.

 

9.1.11   
As of the Effective Date, Sera has not granted any licenses, authorizations or covenants-not-to-sue to any third parties with respect
to the Test in the Field in the Territory, or granted any third party the right to market, offer, perform, sell or distribute testing
services based on use of the Test in the Field in the Territory

 

9.2           
By LabCorp. LabCorp represents, warrants and covenants to Sera that:

 

9.2.1       
This Agreement is a legal and valid obligation binding upon LabCorp and enforceable in accordance with its terms, subject to generally
applicable Legal Requirements, and the execution, delivery and performance of this Agreement by LabCorp does not conflict with any agreement,
instrument or understanding to which LabCorp is a party or by which it is bound.

 

9.2.2       
LabCorp will perform this Agreement and Commercialize Tests in compliance with all applicable federal, state, and local laws, rules,
and regulations and all applicable regulations, rules, and policies of third party payors that pay for the Tests.

 

9.2.3       
LabCorp’s employees who will be performing work under this Agreement are qualified to do so, and possess the necessary skill,
education, training, and where required by any applicable Legal Requirements, Sera and its employees have the necessary federal and state
licenses or certificates, to perform such work.

 

9.2.4       
As of the Effective Date, neither LabCorp nor any of its Affiliates or its or their officers, directors, employees or owners have
been debarred, suspended, declared ineligible or excluded from participation in any federal or state healthcare program and during the
term of this Agreement no officer, director or employee that has been debarred, suspended, declared ineligible or excluded from participation
in any federal or state healthcare program shall perform any services under this Agreement.

 

9.3          
Disclaimer. EXCEPT AS SPECIFIED IN THIS AGREEMENT, EACH PARTY DISCLAIMS ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, WITH
RESPECT TO THE SERVICES, TESTS, THE MARKETING MATERIALS AND ITS TRADEMARKS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT.

 

    10

     

    

 

		10.	TERM AND TERMINATION

 

10.1         
[***].

 

10.2         
Termination.

 

(a)              
[***].

 

(b)              
[***].

 

(c)              
[***].

 

(d)              
Each Party may terminate this Agreement upon notice if the other Party: (i) makes an assignment or other arrangement for the benefit
of creditors, appoints or suffers appointment of a receiver or trustee over its property, (ii) files a petition under any bankruptcy or
insolvency act or has any such petition filed against it which is not discharged within one hundred twenty (120) days of the filing thereof,
(iii) discontinues or suspends its operations for any reason whatsoever, including loss or suspension of license or accreditation, or
(iv) is sanctioned, debarred, suspended, or excluded from any federal health care program as defined under applicable Legal Requirements.

 

(e)              
[***].

 

10.3        
Effects of Expiration or Termination. All licenses granted hereunder to LabCorp shall automatically terminate upon expiration
or termination of this Agreement. Upon termination of this Agreement, each Party shall immediately return to the other party all of the
other Party’s Confidential Information in its possession or control, and LabCorp shall immediately return, at LabCorp’s cost,
all demonstration Tests that have been provided to LabCorp by or on behalf of Sera. Notwithstanding the foregoing, each Party may retain
one copy of the Confidential Information of the other Party in its Law Department for archive purposes, and neither Party shall be required
to destroy or delete copies that have become embedded in its electronic storage systems through routine backup processes. Upon termination
or expiration of this Agreement, LabCorp agrees to cooperate with Sera in order to effect an orderly transition of LabCorp’s responsibilities
hereunder to Sera. Upon expiration or termination of this Agreement, Sera shall complete the performance of any Tests ordered by LabCorp
prior to the date of notice of termination, and Sera shall pay LabCorp all Subcontract Fees due and payable under this Agreement.

 

10.4         
Survival. All rights of a Party that accrued prior to the date of expiration or termination of this Agreement shall be unaffected
by this Agreement’s expiration or termination. Sections 2.10, 2.13, 3.11, 7.1, 7.2, 7.3, 8, 10.3, 10.4 and 11 shall survive the
termination or expiration of this Agreement.

 

		11.	GENERAL PROVISIONS

 

11.1        
Affiliates. LabCorp’s Affiliates shall be permitted to exercise any of LabCorp’s rights under this Agreement,
including without limitation, LabCorp’s rights to accept orders for, sell, and market the Test in the Territory. In addition, Sera
is permitted to perform its obligations and exercise its rights hereunder through one or more Sera Affiliates, including, without limitation,
to perform the Test on Samples delivered hereunder. Each Party is responsible for ensuring that any Affiliates performing obligations
or exercising rights under this Agreement comply with all applicable provisions hereof, and will be fully liable for any actions or omissions
of any such Affiliates in connection therewith, including, without limitation, for any breach of any provision of this Agreement by any
such Affiliate.

 

    11

     

    

 

11.2         
Force Majeure. If either Party is impeded in fulfilling its undertakings in accordance with this Agreement by circumstances
beyond its reasonable control, including labor conflict, acts of God, earthquake, fire, war or terrorist attack, the impediment shall
be considered a “Force Majeure” condition and the Party shall be excused from liability for delays due to such reasons; provided,
however, that it notifies the other Party thereof without undue delay after such a circumstance has occurred. Upon such notification,
the Parties shall agree upon a reasonable extension of the time for performance, not to exceed an extension equal to the period the Force
Majeure condition continues to exist and a reasonable period of time thereafter.

 

11.3         
Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter
hereof and supersedes any and all other agreements, either oral or written, between the Parties with respect to the subject matter hereof.

 

11.4         
Publicity. The Parties shall, upon the Effective Date, work together diligently and in good faith to prepare a joint press
release disclosing their relationship under this Agreement, and each Party may release such press release at any time after thirty (30)
days from the Effective Date. Except for such press release, and except with respect to matters disclosed therein, neither Party shall
make any media releases, public announcements and/or public disclosures relating to this Agreement or the subject matter hereof, including,
without limitation, promotional or marketing material referring to the other Party, without the other Party’s prior written consent,
except as required by Legal Requirements.

 

11.5         
No Implied Licenses or Rights. Except as expressly set forth herein, neither Party shall have the right to use any name,
trademark or service mark of the other Party. Except as expressly set forth herein, nothing in this Agreement shall imply that either
Party has any license or right under the other Party’s Patent Rights or other intellectual property or other propriety rights.

 

11.6        
Assignment. Neither Party may assign, delegate, subcontract or otherwise transfer this Agreement or any right or obligation
hereunder, in whole or part, without the prior express written consent of the other Party, except that Affiliates may exercise rights
or fulfill obligations under this Agreement as provided in Section 11.1. In addition, Sera may assign this Agreement in connection with
the sale or transfer of all or substantially all of its assets to which this Agreement relates upon written notice to LabCorp, subject
to LabCorp’s rights under Section 10.2(e) in the event of an assignment to a competitor of LabCorp.

 

11.7         
Notice. All notices, requests, and other formal or legal communications to any Party hereto must be in writing and addressed
to the receiving Party’s address set forth below or to any other address as a Party may designate by notice hereunder, and will
either be: (i) delivered by hand, (ii) sent by recognized overnight courier, or (iii) by certified mail, return receipt requested, postage
prepaid.

 

    12

     

    

 

	If to Sera:	Sera Prognostics, Inc.
	 	2749 East Parleys Way, Suite 200
	 	Salt Lake City, Utah 84109
	 	Attention: Chief Financial Officer or
	 	Chief Executive Officer
	 	 
	If to LabCorp:	Laboratory Corporation of America Holdings
	 	531 South Spring Street
	 	Burlington, NC 27215
	 	Attention: Law Department
	 	 
	with a copy sent to:	Laboratory Corporation of America Holdings
	 	531 South Spring Street
	 	Burlington, NC 27215
	 	Attention: Licensing/Corporate Development

 

All notices, requests, and other communication
hereunder will be deemed effective: (a) if by hand, at the time of the delivery thereof to the receiving Party at the address of such
Party set forth above, (b) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier
service, or (c) if sent by certified mail, five (5) business days following the day such mailing is made.

 

11.8         
Amendment/Waiver. The failure of either Party to enforce any term or condition of this Agreement may not be construed as
a waiver by such Party of such term or condition, nor will a waiver of any breach of a term or condition of this Agreement on any one
occasion constitute a waiver of any subsequent breach of the same or similar term or condition. No term or provision of this Agreement
may be changed, waived, amended, or terminated except by a written agreement signed by both Parties.

 

11.9         
Governing Law. This Agreement is governed by the laws of the State of Delaware, without regard to any conflict of laws provisions
contained therein.

 

11.10     
Enforceability/Severability. If any provision of this Agreement is determined to be invalid or unenforceable, such provision
will be deemed severable from the remainder of this Agreement and will not cause the invalidity or unenforceability of the remainder of
this Agreement.

 

11.11     
Headings. The article, section and exhibit headings used herein are for convenience and reference only and may not be used
in the interpretation of this Agreement.

 

11.12     
Counterparts. This Agreement may be executed in one or more counterparts, each of which are be deemed an original, but all
of which together constitute one and the same instrument. Copies of signatures sent by facsimile transmission or in a fixed electronic
format (such as a PDF file) will be deemed to be originals.

 

11.13      Interpretation.
Words such as “herein,” “hereof” and “hereunder” refer to this Agreement as a whole and not
merely to an Article, Section or paragraph in which such words appear, unless the context otherwise requires. The singular shall
include the plural, and each masculine, feminine and neuter reference shall include and refer also to the others, unless the context
otherwise requires. The word “or” is used in the inclusive sense typically associated with the phrase
 “and/or”. The words “include,” “includes” and “including” shall be deemed to be
followed by the phrase “without limitation” and shall not be construed to limit any general statement which it follows
to the specific or similar items or matters immediately following it. The word “will” shall be construed to have the
same meaning and effect as the word “shall.” All references herein to Articles, Sections or Exhibits shall be construed
to refer to Articles, Sections and Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto.

 

[SIGNATURES APPEAR ON THE FOLLOWING PAGE]

 

    13

     

    

 

IN WITNESS WHEREOF, the duly
authorized representatives of the Parties have executed this Agreement effective as of the Effective Date.

 

	SERA PROGNOSTICS, INC.	 	LABORATORY CORPORATION OF AMERICA HOLDINGS
	 	 	 
	By:	/s/ Gregory C. Critchfield, M.D.,MS	 	By:	/s/ Eric Lindblom
	 	 	 
	Name: Gregory C. Critchfield, M.D., MS	 	Name: Eric Lindblom
	 	 	 
	Its: President and Chief Executive Officer	 	Its: SVP

 

     

     

    

 

EXHIBIT A

 

[***]

 

     

     

    

 

 

EXHIBIT B

 

[***]

 

     

     

    

 

EXHIBIT C

 

[***]

 

     

     

    

 

EXHIBIT D

 

[***]

 

     

     

    

 

EXHIBIT E

 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]